Project/Area Number |
21890055
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Single-year Grants |
Research Field |
Hematology
|
Research Institution | The University of Tokyo |
Principal Investigator |
SATO Tomohiko The University of Tokyo, 医学部附属病院, 特任臨床医 (90553694)
|
Project Period (FY) |
2009 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2010: ¥1,235,000 (Direct Cost: ¥950,000、Indirect Cost: ¥285,000)
Fiscal Year 2009: ¥1,365,000 (Direct Cost: ¥1,050,000、Indirect Cost: ¥315,000)
|
Keywords | 癌 / 白血病 / 幹細胞 |
Research Abstract |
We have recently generated Evi-1-GFP knock-in mice, which can trace Evi1 mRNA level in vivo, and we revealed that Evi-1 is highly expressed at both fetal and adult hematopoietic stem cells (HSCs). In addition, we also clarified that Evi-1 positive murine HSC (KSL) function as long-term HSC by bone marrow transplantation assay, and that Evi-1 can mark long-term HSC which is the most immature hematopoietic cells. (These data are now on submission) Next, for the analysis of leukemia stem cell regulation by Evi-1, we made chronic myeloid leukemia (CML) mouse of Evi-1-GFP knockin origin by using BCR-ABL oncogene. We revealed that Evi-1 positive KSL cells had highest Evi-1 expression in these model mice which implied that Evi-1 could regulate CML stem cells. Our original analysis of leukemia stem cell is still ongoing for the purpose of establishing specific therapy of CML stem cells.
|